MOMA Therapeutics Appoints Susan Pandya, M.D., to Board of Directors and Expands Management Team
MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics today announced the appointment of Susan Pandya, M.D., as an independent member of the company’s board of directors.
MOMA Therapeutics Provides Corporate Update and Announces Exclusive License Agreement for Selective PARP1 Inhibitor
MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in-licensing of a next-generation selective PARP1 (poly ADP-ribose polymerase) inhibitor, now known as MOMA-989. The company also provided an update on the clinical progress of Polθ inhibitor MOMA-313 and outlined the clinical path for Werner inhibitor MOMA-341.
MOMA Therapeutics Announces Initiation of Phase 1 Clinical Trial for MOMA-313, a Novel Polymerase Theta Helicase Inhibitor
MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced that the first patient has been dosed in its Phase 1 clinical trial to assess the safety and tolerability of MOMA-313, a novel, highly potent and selective oral polymerase theta helicase inhibitor.
MOMA Therapeutics Appoints Marc Ballas, M.D., as Head of Clinical Development, and Adam Thomas as Chief People & Experience Officer
MOMA Therapeutics, a biopharmaceutical company discovering and developing a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced the appointments of two seasoned industry executives to the company’s leadership team. Marc Ballas, M.D., joins as SVP, head of clinical development, and Adam Thomas joins as chief people and experience officer.
MOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer
MOMA Therapeutics, a biopharmaceutical company discovering and developing a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced that Jullian G. Jones, Ph.D., J.D., MBA, has been appointed as the company’s chief business officer. In this role, Dr. Jones will be responsible for guiding MOMA’s corporate and business strategy, which includes investor relations, business development, new product planning, and oversight of strategic finance and accounting.
MOMA Therapeutics Announces Five-Year Discovery Collaboration with Roche Focused on Critical Cancer Dependencies
MOMA Therapeutics, a biotechnology company focused on identifying and targeting highly dynamic, difficult to drug targets in cancer and other diseases, is pleased to announce a strategic collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY). This partnership provides Roche with access to MOMA’s proprietary KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer cell growth and survival.
MOMA Therapeutics Appoints Industry Leader Jeff Albers as Chair of the Board of Directors
MOMA Therapeutics, a biopharmaceutical company discovering a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced the appointment of Jeff Albers as independent chairperson of the company’s board of directors.
MOMA Therapeutics Announces $150 Million Series B Financing
MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced the completion of a $150 million Series B financing. The financing was led by Goldman Sachs Asset Management, with participation from other new investors Section 32, Pavilion Capital, Invus and LifeSci Venture Partners. All of MOMA’s Series A investors, including Third Rock Ventures, Nextech Invest, Cormorant Asset Management, Casdin Capital, Rock Springs Capital, Creacion Ventures, Alexandria Venture Investments and other undisclosed investors, also participated in the round.
MOMA Therapeutics Appoints Hans Bitter, Ph.D., as Senior Vice President and Head, Data Science
MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced the appointment of Hans Bitter, Ph.D., as senior vice president and head, data science. In this inaugural role, Dr. Bitter will lead MOMA’s team of scientists, engineers and modelers to mine biological and chemical data to advance MOMA’s research and development efforts. In addition, MOMA further expanded its leadership team with the addition on Nazareth Martinez Shedden as vice president, strategic finance.
MOMA Therapeutics Appoints Semi Trotto as Chief People and Experience Officer
MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced that Semi Trotto has been appointed as the company’s chief people and experience officer. In this newly created role, Ms. Trotto will be responsible for helping develop MOMA’s people, shaping company culture, and managing internal and external communications, facilities and administration.
MOMA Therapeutics Appoints Peter Hammerman, M.D., Ph.D., as Chief Scientific Officer
MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced that Peter Hammerman, M.D., Ph.D., has been appointed as the company’s chief scientific officer. A leading cancer biologist and oncologist, Dr. Hammerman joins MOMA from Novartis Institutes of Biomedical Research, where he was global head of oncology translational research.
